SPECTamine (iofetamine HClI-123 injection
Executive SummarySyncor International announces an exclusive U.S. distribution agreement for the brain imaging agent with Houston-based IMP Inc. The product had been distributed by Roche subsidiary Medi-Physics. The new agreement goes into effect when the sale of Medi-Physics to Amersham is finalized. Amersham recently announced a restructuring of its deal with Roche to acquire Medi-Physics.
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.